Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis
Go back to Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis| Incyte Genomics, Inc. (NASDAQ: INCY) | Delayed: 124.40 -2.35 (1.85%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $126.75 | 52 Week High | $118.49 | |||
| Open | $124.11 | 52 Week Low | $55.00 | |||
| Day High | $126.40 | P/E | N/A | |||
| Day Low | $122.22 | EPS | $-0.56 | |||
| Volume | 1,283,253 | |||||
